Monday 26 March 2018

Ovarian Cancer Market To Observe Strong Development By 2017


Overview
Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, changes in bowel habits, such as constipation, loss of appetite and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy and radiation therapy.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Ovarian Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 2, 15, 135, 128, 7, 208, 21 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 11, 14, 43 and 8 molecules, respectively.
 Major Scope of the report:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Ovarian Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects. 
Table of Contents 
Table of Contents 2
Introduction 12
Ovarian Cancer - Overview 13
Ovarian Cancer - Therapeutics Development 14
Ovarian Cancer - Therapeutics Assessment 73
Ovarian Cancer - Companies Involved in Therapeutics Development 105
Ovarian Cancer - Drug Profiles 254
Ovarian Cancer - Dormant Projects 1928
Ovarian Cancer - Discontinued Products 1947
Ovarian Cancer - Product Development Milestones 1951
Appendix 1968
 .Continued
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)

Global Colorectal Cancer Industry Trends, Regulations And Competitive Landscape Outlook


Overview
Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Colorectal Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Colorectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Colorectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 25, 108, 137, 10, 173, 26 and 10 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 18, 9, 28 and 5 molecules, respectively.
 Major Scope of the report:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Colorectal Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Colorectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Colorectal Cancer (Oncology) therapeutics and enlists all their major and minor projects. 


Table of Contents 
Table of Contents 2
Introduction 11
Colorectal Cancer - Overview 12
Colorectal Cancer - Therapeutics Development 13
Colorectal Cancer - Therapeutics Assessment 66
Colorectal Cancer - Companies Involved in Therapeutics Development 94
Colorectal Cancer - Drug Profiles 223
Colorectal Cancer - Dormant Projects 1708
Colorectal Cancer - Discontinued Products 1725
Colorectal Cancer - Product Development Milestones 1730
Appendix 1745
 .Continued
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)

Recurrent Malignant Glioma Industry Market Trends, Size And Growth Analysis 2017 To 2022


Overview
Recurrent malignant glioma is defined as recurrence of tumor after treatment. Symptoms include chest pain due to a tumor located in the chest area of the spinal cord, erectile dysfunction, lack of ability to feel changes in temperature, loss of muscle control, loss of bowel or bladder control, numbness or tingling, pain in the arm, neck, back, or leg caused by tumors in the neck area of the spinal cord and weakness in the limbs or upper body. Treatment includes chemotherapy and radiation therapy
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Recurrent Malignant Glioma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Recurrent Malignant Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Recurrent Malignant Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Recurrent Malignant Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 2 and 1 molecules, respectively.
 Major Scope of the report:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Recurrent Malignant Glioma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Recurrent Malignant Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. 


Table of Contents 
List of Figures
Introduction
Global Markets Direct Report Coverage
Recurrent Malignant Glioma - Overview
Recurrent Malignant Glioma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Recurrent Malignant Glioma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Recurrent Malignant Glioma - Companies Involved in Therapeutics Development
AbbVie Inc
GtreeBNT Co Ltd
Recurrent Malignant Glioma - Drug Profiles
 .Continued
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)

Latest Study Offers Detailed Insights On Acute Myelocytic Leukemia Industry 2017


Overview
Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the blood stream and spread to the other parts of the body. Symptoms for AML include fatigue, fever, bleeding, breathing problems, weight loss. The predisposing factors involved are exposure to radiation or chemicals and smoking. Treatment includes chemotherapy, transfusions, transplant and surgery.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 18, 98, 105, 1, 5, 171, 14 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 16, 14, 31 and 13 molecules, respectively.
 Major Scope of the report:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. 


Table of Contents 
Introduction 10
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Overview 11
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Development 12
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Assessment 71
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Companies Involved in Therapeutics Development 100
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Drug Profiles 218
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects 1600
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products 1612
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Product Development Milestones 1616
Appendix 1628
.Continued
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)

Global Therapeutic Landscape Of Rheumatoid Arthritis Industry Pipeline Review, 2017


Overview
Rheumatoid arthritis (RA) is an autoimmune chronic disorder that eventually leads to destruction of bones causing deformities. Signs and symptoms of rheumatoid arthritis include tender, warm, swollen joints, fatigue, and fever and weight loss. Rheumatoid arthritis may be a result of genetic and certain specific environmental factors. Women are much more susceptible to develop RA. Treatment includes non-steroidal anti-inflammatory drugs, corticosteroid medications and immunosuppressants.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Rheumatoid Arthritis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Rheumatoid Arthritis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Rheumatoid Arthritis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Rheumatoid Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 17, 27, 48, 62, 7, 223, 52 and 7 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 37 and 12 molecules, respectively.
 Major Scope of the report:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis (Immunology).
- The pipeline guide reviews pipeline therapeutics for Rheumatoid Arthritis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rheumatoid Arthritis (Immunology) therapeutics and enlists all their major and minor projects. 


Table of Contents 
Introduction 10
Rheumatoid Arthritis - Overview 11
Rheumatoid Arthritis - Therapeutics Development 12
Rheumatoid Arthritis - Therapeutics Assessment 60
Rheumatoid Arthritis - Companies Involved in Therapeutics Development 82
Rheumatoid Arthritis - Drug Profiles 194
Rheumatoid Arthritis - Dormant Projects 919
Rheumatoid Arthritis - Discontinued Products 948
Rheumatoid Arthritis - Product Development Milestones 955
Appendix 972
List of Tables
Number of Products under Development for Rheumatoid Arthritis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
.Continued
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)

Recent Study Explores Vasomotor Symptoms of Menopause (Hot Flashes) Industry Pipeline Review, 2017

Overview
Vasomotor symptoms of menopause include hot flashes or night sweats that result from sudden opening of the blood vessels close to the skin, usually due to hormonal fluctuations in menopause and perimenopause. These symptoms are caused due to some medications, estrogen withdrawal, thyroid disease, diabetes, hyperhidrosis, anxiety and panic disorders, obesity, hormonally active tumors, chronic infections and neurological disorders.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Vasomotor Symptoms of Menopause (Hot Flashes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 6, 2 and 3 respectively.
 Major Scope of the report:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health). 
- The pipeline guide reviews pipeline therapeutics for Vasomotor Symptoms of Menopause (Hot Flashes) (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. 

Table of Contents 
List of Figures
Introduction
Global Markets Direct Report Coverage
Vasomotor Symptoms of Menopause (Hot Flashes) - Overview
Vasomotor Symptoms of Menopause (Hot Flashes) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Vasomotor Symptoms of Menopause (Hot Flashes) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Vasomotor Symptoms of Menopause (Hot Flashes) - Companies Involved in Therapeutics Development
EndoCeutics Inc
MenoGeniX Inc
Millendo Therapeutics Inc
Mithra Pharmaceuticals SA
Ogeda SA 
.Continued
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Female Contraception Industry Anticipated To Witness Noteworthy Growth In The Coming Years


Overview
Contraception (birth control) prevents pregnancy by interfering with the normal process of ovulation, fertilization, and implantation. There are many contraceptive methods which include implants and injections, intrauterine devices (IUDs), pills and vaginal rings, barrier methods, sterilization and natural methods. Contraception generally work by preventing sperm from reaching and fertilizing an egg (barrier and IUD methods), preventing an egg from being released every month (hormones), blocking the reproductive function (sterilization) and preventing a fertilized egg from implanting in the uterus (hormones).
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Female Contraception - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Female Contraception (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Female Contraception (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Contraception and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 6, 3, 6 and 5 respectively. Similarly, the Universities portfolio in Phase III and Preclinical stages comprises 1 and 2 molecules, respectively.
Female Contraception (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
 Major Scope of the report:
- The pipeline guide provides a snapshot of the global therapeutic landscape of Female Contraception (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Female Contraception (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Female Contraception (Women's Health) therapeutics and enlists all their major and minor projects. 
Table of Contents 
List of Figures
Introduction
Global Markets Direct Report Coverage
Female Contraception - Overview
Female Contraception - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Female Contraception - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Female Contraception - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Agile Therapeutics Inc
Bayer AG
Evofem Inc
Hervana Ltd
Mithra Pharmaceuticals SA 
.Continued
About Us
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)